| Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases. Co.'s business segments are: Specialized BioTherapeutics, which is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma; and Public Health Solutions, which includes development programs for RiVax®, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and other infectious disease and its vaccine programs targeting filoviruses and CiVax, its vaccine candidate for the prevention of COVID-19. We show 29 historical shares outstanding datapoints in our coverage of SNGX's shares outstanding history.
Understanding the changing numbers of SNGX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SNGX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SNGX by allowing them to research SNGX shares outstanding history
as well as any other stock in our coverage universe.